Cargando…

Lessons learned from the COVID-19 pandemic about sample access for research in the UK

OBJECTIVE: Annotated clinical samples taken from patients are a foundation of translational medical research and give mechanistic insight into drug trials. Prior research by the Tissue Directory and Coordination Centre (TDCC) indicated that researchers, particularly those in industry, face many barr...

Descripción completa

Detalles Bibliográficos
Autores principales: Sims, Jessica M, Lawrence, Emma, Glazer, Katy, Gander, Amir, Fuller, Barry, Davidson, Brian R, Garibaldi, Jonathan, Quinlan, Philip R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013782/
https://www.ncbi.nlm.nih.gov/pubmed/35428611
http://dx.doi.org/10.1136/bmjopen-2020-047309
_version_ 1784688069428903936
author Sims, Jessica M
Lawrence, Emma
Glazer, Katy
Gander, Amir
Fuller, Barry
Davidson, Brian R
Garibaldi, Jonathan
Quinlan, Philip R
author_facet Sims, Jessica M
Lawrence, Emma
Glazer, Katy
Gander, Amir
Fuller, Barry
Davidson, Brian R
Garibaldi, Jonathan
Quinlan, Philip R
author_sort Sims, Jessica M
collection PubMed
description OBJECTIVE: Annotated clinical samples taken from patients are a foundation of translational medical research and give mechanistic insight into drug trials. Prior research by the Tissue Directory and Coordination Centre (TDCC) indicated that researchers, particularly those in industry, face many barriers in accessing patient samples. The arrival of the COVID-19 pandemic to the UK produced an immediate and extreme shockwave, which impacted on the ability to undertake all crucial translational research. As a national coordination centre, the TDCC is tasked with improving efficiency in the biobanking sector. Thus, we took responsibility to identify and coordinate UK tissue sample collection organisations (biobanks) able to collect COVID-19-related samples for researchers between March and September 2020. FINDINGS: Almost a third of UK biobanks were closed during the first wave of the UK COVID-19 pandemic. Of the remainder, 43% had limited capabilities while 26% maintained normal activity. Of the nationally prioritised COVID-19 interventional studies, just three of the five that responded to questioning were collecting human samples. Of the 41 requests for COVID-19 samples received by the TDCC, only four could be fulfilled due to a lack of UK coordinated strategy. Meanwhile, in the background there are numerous reports that sample collections in the UK remain largely underutilised. CONCLUSION: The response to a pandemic demands high level co-ordinated research responses to reduce mortality. Our study highlights the lack of efficiency and coordination between human sample collections and clinical trials across the UK. UK sample access is not working for researchers, clinicians or patients. A radical change is required in the strategy for sample collection and distribution to maximise this valuable resource of human-donated samples.
format Online
Article
Text
id pubmed-9013782
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-90137822022-04-20 Lessons learned from the COVID-19 pandemic about sample access for research in the UK Sims, Jessica M Lawrence, Emma Glazer, Katy Gander, Amir Fuller, Barry Davidson, Brian R Garibaldi, Jonathan Quinlan, Philip R BMJ Open Communication OBJECTIVE: Annotated clinical samples taken from patients are a foundation of translational medical research and give mechanistic insight into drug trials. Prior research by the Tissue Directory and Coordination Centre (TDCC) indicated that researchers, particularly those in industry, face many barriers in accessing patient samples. The arrival of the COVID-19 pandemic to the UK produced an immediate and extreme shockwave, which impacted on the ability to undertake all crucial translational research. As a national coordination centre, the TDCC is tasked with improving efficiency in the biobanking sector. Thus, we took responsibility to identify and coordinate UK tissue sample collection organisations (biobanks) able to collect COVID-19-related samples for researchers between March and September 2020. FINDINGS: Almost a third of UK biobanks were closed during the first wave of the UK COVID-19 pandemic. Of the remainder, 43% had limited capabilities while 26% maintained normal activity. Of the nationally prioritised COVID-19 interventional studies, just three of the five that responded to questioning were collecting human samples. Of the 41 requests for COVID-19 samples received by the TDCC, only four could be fulfilled due to a lack of UK coordinated strategy. Meanwhile, in the background there are numerous reports that sample collections in the UK remain largely underutilised. CONCLUSION: The response to a pandemic demands high level co-ordinated research responses to reduce mortality. Our study highlights the lack of efficiency and coordination between human sample collections and clinical trials across the UK. UK sample access is not working for researchers, clinicians or patients. A radical change is required in the strategy for sample collection and distribution to maximise this valuable resource of human-donated samples. BMJ Publishing Group 2022-04-15 /pmc/articles/PMC9013782/ /pubmed/35428611 http://dx.doi.org/10.1136/bmjopen-2020-047309 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
spellingShingle Communication
Sims, Jessica M
Lawrence, Emma
Glazer, Katy
Gander, Amir
Fuller, Barry
Davidson, Brian R
Garibaldi, Jonathan
Quinlan, Philip R
Lessons learned from the COVID-19 pandemic about sample access for research in the UK
title Lessons learned from the COVID-19 pandemic about sample access for research in the UK
title_full Lessons learned from the COVID-19 pandemic about sample access for research in the UK
title_fullStr Lessons learned from the COVID-19 pandemic about sample access for research in the UK
title_full_unstemmed Lessons learned from the COVID-19 pandemic about sample access for research in the UK
title_short Lessons learned from the COVID-19 pandemic about sample access for research in the UK
title_sort lessons learned from the covid-19 pandemic about sample access for research in the uk
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013782/
https://www.ncbi.nlm.nih.gov/pubmed/35428611
http://dx.doi.org/10.1136/bmjopen-2020-047309
work_keys_str_mv AT simsjessicam lessonslearnedfromthecovid19pandemicaboutsampleaccessforresearchintheuk
AT lawrenceemma lessonslearnedfromthecovid19pandemicaboutsampleaccessforresearchintheuk
AT glazerkaty lessonslearnedfromthecovid19pandemicaboutsampleaccessforresearchintheuk
AT ganderamir lessonslearnedfromthecovid19pandemicaboutsampleaccessforresearchintheuk
AT fullerbarry lessonslearnedfromthecovid19pandemicaboutsampleaccessforresearchintheuk
AT davidsonbrianr lessonslearnedfromthecovid19pandemicaboutsampleaccessforresearchintheuk
AT garibaldijonathan lessonslearnedfromthecovid19pandemicaboutsampleaccessforresearchintheuk
AT quinlanphilipr lessonslearnedfromthecovid19pandemicaboutsampleaccessforresearchintheuk